Berberine hydrochloride could prove to be a promising bullet against Clostridium difficile infection

A preliminary study from South India

Rituparna Chakraborty, Richard Lobo, Mukhyaprana M. Prabhu, Shashikiran Umakanth, Goutam Chowdhury, Asish K. Mukhopadhyay, T. Ramamurthy, Mamatha Ballal

Research output: Contribution to journalArticle

Abstract

Objective: Recurrent Clostridium difficile infection (CDI) and the emergence of strains with reduced susceptibility to metronidazole and vancomycin warrants alternative therapy. Hence, we tested the potential efficacy of the natural compound berberine hydrochloride (BBRHCl) against toxigenic C. difficile. Methods: Three representative polymerase chain reaction confirmed, toxin-positive strains were included in the study. Pulsed-field gel electrophoresis (PFGE) profile and antibiogram of the strains were analyzed along with 10 other toxin positive isolates. Efficacy of BBRHCl against toxigenic C. difficile was determined using agar diffusion by punch well method. Results: PFGE grouped the test strains into three clusters with unique susceptibility pattern toward standard antibiotics. BBRHCl was efficacious against the test strains at a concentration ranging between 6.25 µg/ml and 10 mg/ml. BBRHCl’s breakpoint point inhibitory zone diameter was equivalent (p<0.001) to the epidemiological cutoff values for teicoplanin, vancomycin and 2% black seed oil. Although the predicted concentration of BBRHCl for breakpoint zone diameter equivalent to European Committee on Antimicrobial Susceptibility Testing’s epidemiological cutoff value for metronidazole was observed to fall outside the tested concentration range; it was still within the safe dosage for humans. Conclusion: The present study is promising in considering BBRHCl as a potent substitute or adjunct not only for metronidazole, vancomycin and teicoplanin but also for natural compounds like 2% black seed oil for managing resistant cases of CDI. Owing to BBRHCl’s direct antibacterial and antiinflammatory action, further investigations will aid in the proper characterization of the therapeutic effects of similar plant compounds, to develop safe and effective drugs against the epidemiological outbreak of CDI.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number12
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Berberine
Clostridium Infections
Clostridium difficile
India
Metronidazole
Vancomycin
Teicoplanin
Pulsed Field Gel Electrophoresis
Seeds
Oils
Microbial Sensitivity Tests
Therapeutic Uses
Complementary Therapies
Agar
Disease Outbreaks
Anti-Inflammatory Agents
Anti-Bacterial Agents
Polymerase Chain Reaction
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{6bffc12e437f40fcac3260769ec510c6,
title = "Berberine hydrochloride could prove to be a promising bullet against Clostridium difficile infection: A preliminary study from South India",
abstract = "Objective: Recurrent Clostridium difficile infection (CDI) and the emergence of strains with reduced susceptibility to metronidazole and vancomycin warrants alternative therapy. Hence, we tested the potential efficacy of the natural compound berberine hydrochloride (BBRHCl) against toxigenic C. difficile. Methods: Three representative polymerase chain reaction confirmed, toxin-positive strains were included in the study. Pulsed-field gel electrophoresis (PFGE) profile and antibiogram of the strains were analyzed along with 10 other toxin positive isolates. Efficacy of BBRHCl against toxigenic C. difficile was determined using agar diffusion by punch well method. Results: PFGE grouped the test strains into three clusters with unique susceptibility pattern toward standard antibiotics. BBRHCl was efficacious against the test strains at a concentration ranging between 6.25 µg/ml and 10 mg/ml. BBRHCl’s breakpoint point inhibitory zone diameter was equivalent (p<0.001) to the epidemiological cutoff values for teicoplanin, vancomycin and 2{\%} black seed oil. Although the predicted concentration of BBRHCl for breakpoint zone diameter equivalent to European Committee on Antimicrobial Susceptibility Testing’s epidemiological cutoff value for metronidazole was observed to fall outside the tested concentration range; it was still within the safe dosage for humans. Conclusion: The present study is promising in considering BBRHCl as a potent substitute or adjunct not only for metronidazole, vancomycin and teicoplanin but also for natural compounds like 2{\%} black seed oil for managing resistant cases of CDI. Owing to BBRHCl’s direct antibacterial and antiinflammatory action, further investigations will aid in the proper characterization of the therapeutic effects of similar plant compounds, to develop safe and effective drugs against the epidemiological outbreak of CDI.",
author = "Rituparna Chakraborty and Richard Lobo and Prabhu, {Mukhyaprana M.} and Shashikiran Umakanth and Goutam Chowdhury and Mukhopadhyay, {Asish K.} and T. Ramamurthy and Mamatha Ballal",
year = "2017",
month = "1",
day = "1",
doi = "10.22159/ajpcr.2017.v10i12.21932",
language = "English",
volume = "10",
pages = "419--424",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "12",

}

Berberine hydrochloride could prove to be a promising bullet against Clostridium difficile infection : A preliminary study from South India. / Chakraborty, Rituparna; Lobo, Richard; Prabhu, Mukhyaprana M.; Umakanth, Shashikiran; Chowdhury, Goutam; Mukhopadhyay, Asish K.; Ramamurthy, T.; Ballal, Mamatha.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 12, 01.01.2017, p. 419-424.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Berberine hydrochloride could prove to be a promising bullet against Clostridium difficile infection

T2 - A preliminary study from South India

AU - Chakraborty, Rituparna

AU - Lobo, Richard

AU - Prabhu, Mukhyaprana M.

AU - Umakanth, Shashikiran

AU - Chowdhury, Goutam

AU - Mukhopadhyay, Asish K.

AU - Ramamurthy, T.

AU - Ballal, Mamatha

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: Recurrent Clostridium difficile infection (CDI) and the emergence of strains with reduced susceptibility to metronidazole and vancomycin warrants alternative therapy. Hence, we tested the potential efficacy of the natural compound berberine hydrochloride (BBRHCl) against toxigenic C. difficile. Methods: Three representative polymerase chain reaction confirmed, toxin-positive strains were included in the study. Pulsed-field gel electrophoresis (PFGE) profile and antibiogram of the strains were analyzed along with 10 other toxin positive isolates. Efficacy of BBRHCl against toxigenic C. difficile was determined using agar diffusion by punch well method. Results: PFGE grouped the test strains into three clusters with unique susceptibility pattern toward standard antibiotics. BBRHCl was efficacious against the test strains at a concentration ranging between 6.25 µg/ml and 10 mg/ml. BBRHCl’s breakpoint point inhibitory zone diameter was equivalent (p<0.001) to the epidemiological cutoff values for teicoplanin, vancomycin and 2% black seed oil. Although the predicted concentration of BBRHCl for breakpoint zone diameter equivalent to European Committee on Antimicrobial Susceptibility Testing’s epidemiological cutoff value for metronidazole was observed to fall outside the tested concentration range; it was still within the safe dosage for humans. Conclusion: The present study is promising in considering BBRHCl as a potent substitute or adjunct not only for metronidazole, vancomycin and teicoplanin but also for natural compounds like 2% black seed oil for managing resistant cases of CDI. Owing to BBRHCl’s direct antibacterial and antiinflammatory action, further investigations will aid in the proper characterization of the therapeutic effects of similar plant compounds, to develop safe and effective drugs against the epidemiological outbreak of CDI.

AB - Objective: Recurrent Clostridium difficile infection (CDI) and the emergence of strains with reduced susceptibility to metronidazole and vancomycin warrants alternative therapy. Hence, we tested the potential efficacy of the natural compound berberine hydrochloride (BBRHCl) against toxigenic C. difficile. Methods: Three representative polymerase chain reaction confirmed, toxin-positive strains were included in the study. Pulsed-field gel electrophoresis (PFGE) profile and antibiogram of the strains were analyzed along with 10 other toxin positive isolates. Efficacy of BBRHCl against toxigenic C. difficile was determined using agar diffusion by punch well method. Results: PFGE grouped the test strains into three clusters with unique susceptibility pattern toward standard antibiotics. BBRHCl was efficacious against the test strains at a concentration ranging between 6.25 µg/ml and 10 mg/ml. BBRHCl’s breakpoint point inhibitory zone diameter was equivalent (p<0.001) to the epidemiological cutoff values for teicoplanin, vancomycin and 2% black seed oil. Although the predicted concentration of BBRHCl for breakpoint zone diameter equivalent to European Committee on Antimicrobial Susceptibility Testing’s epidemiological cutoff value for metronidazole was observed to fall outside the tested concentration range; it was still within the safe dosage for humans. Conclusion: The present study is promising in considering BBRHCl as a potent substitute or adjunct not only for metronidazole, vancomycin and teicoplanin but also for natural compounds like 2% black seed oil for managing resistant cases of CDI. Owing to BBRHCl’s direct antibacterial and antiinflammatory action, further investigations will aid in the proper characterization of the therapeutic effects of similar plant compounds, to develop safe and effective drugs against the epidemiological outbreak of CDI.

UR - http://www.scopus.com/inward/record.url?scp=85037644850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037644850&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i12.21932

DO - 10.22159/ajpcr.2017.v10i12.21932

M3 - Article

VL - 10

SP - 419

EP - 424

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 12

ER -